hotspot -WSS

hotspot

author：hotspot 2025-10-01 10:59:26 - browse：9474

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： NEJM study measures Covid brain fog, impact on IQ

WSS

Neuroscience renaissance leads to new crop of psychiatric drugs

How to make the FDA’s new prescription one

'Vaccine

Food makers tried to stack nutrition panel with preferred experts

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Neuroscience renaissance leads to new crop of psychiatric drugs

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Pfizer is about to make a big push in cancer. Will investors listen?

Affirmative action in medical school literally saved lives

Change Healthcare cyberattack shows risk of industry consolidation

Duchenne breakthrough therapy leaves behind pioneering families

Ohio train derailment: Experts on toxic chemical risks

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Tori Bowie and the unacceptable rates of Black maternal death

CDC panel: People 65 and older should get a Covid spring booster shot

Wikipedia

Medicare isn't yet testing food as medicine

CDC panel: People 65 and older should get a Covid spring booster shot

FDA proposes changes to key medical devices approval pathway

Medicare isn't yet testing food as medicine

Diverse clinical trials: Why aren’t we there yet?

STAT Madness 2024: Meet the contenders

focus

focus

explore

leisure time